The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
Participant must have advanced, unresectable or metastatic cancer (solid tumors)
Participant must not have known HIV infection or hepatitis A, B, or C
Participant must not have current blood cancers, acute or chronic leukemia
Participant must not have previously completed or withdrawn from this study or any other study investigating an ERK1/2 inhibitor
Female participant must not be pregnant, breastfeeding, or planning to become pregnant
To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled. This website is not optimized for your browser, as configured.